The weekly litigation news digest is live. Subscribe now

IP Verse

Boehringer Ingelheim Pharma competitive analysis

Loading summary...

Latest oppositions filed by Boehringer Ingelheim Pharma

Explore patent oppositions filed by Boehringer Ingelheim Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Dec 11, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3219328
Human Anti-Il-23 Antibodies, Compositions, Method And UsesJANSSEN BIOTECHMar 17, 2021
EP2634243
Improved Process For The Culturing Of CellsDPXJun 5, 2018
EP2634242
Improved Process For The Culturing Of CellsDPXJan 4, 2018
EP2634250
Improved Process For The Culturing Of CellsDPXJan 4, 2018

Latest patents of Boehringer Ingelheim Pharma opposed by its competitors

Explore Boehringer Ingelheim Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Dec 11, 2025
Patent NumberPublication DateTitleTotal Oppositions
EP2152341
Apr 2, 2025Atomizer, And Filter2
EP2397142
Jul 27, 2022Use Of Dpp Iv Inhibitors5
EP2433665
Aug 7, 2019Inhaler And Sieve For An Inhaler1
EP1940349
Feb 14, 2018Aerosol Formulation For The Inhalation Of Beta Agonists1
EP1830843
Nov 7, 2012Indolidone Derivatives For The Treatment Or Prevention Of Fibrotic Diseases1

Latest PTAB cases involving Boehringer Ingelheim Pharma

Discover the latest PTAB cases involving Boehringer Ingelheim Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Dec 14, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Boehringer Ingelheim Pharma

IPR2017-02029Aug 31, 2017BOEHRINGER INGELHEIMGENENTECHTerminated-Settled
IPR2017-02031Aug 31, 2017BOEHRINGER INGELHEIMGENENTECHTerminated
IPR2017-02032Aug 31, 2017BOEHRINGER INGELHEIMGENENTECHTerminated
IPR2016-01563Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIMTerminated
IPR2016-01564Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIMTerminated
IPR2016-01565Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIMTerminated
IPR2016-01566Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIMInstitution Denied
IPR2015-00415Dec 15, 2014BOEHRINGER INGELHEIMGENENTECHTerminated-Settled
IPR2015-00417Dec 15, 2014BOEHRINGER INGELHEIMGENENTECHTerminated-Settled
IPR2015-00418Dec 15, 2014BOEHRINGER INGELHEIMBIOGENInstitution Denied

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Dec 11, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
BOEHRINGER INGELHEIM49179109
DPX - 9 - -
DSM ASSETS2096 - 15
PATHEON I - 9 - -